MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer Cost of Revenue 2011-2026 | PKI
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 1.44 B | - | - | - | - | - | - | 946 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.44 B | 946 M | 1.19 B |
Quarterly Cost of Revenue PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 324 M | 328 M | 289 M | - | 299 M | 306 M | 295 M | - | 298 M | 307 M | 293 M | - | 305 M | 344 M | 368 M | - | 338 M | 543 M | 523 M | - | 437 M | 364 M | 344 M | - | 365 M | 375 M | 341 M | - | 342 M | 363 M | 352 M | - | 285 M | 289 M | 274 M | - | 266 M | 283 M | 263 M | - | 309 M | 311 M | 292 M | - | 299 M | 308 M | 295 M | - | 289 M | 299 M | 280 M | - | 279 M | 283 M | 279 M | - | 254 M | 270 M | 247 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 543 M | 247 M | 320 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
2.91 B | $ 113.25 | -1.38 % | $ 34.4 B |  USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 17.42 | -2.24 % | $ 928 M | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 16.35 | 0.28 % | $ 172 M |  China |
 |
Co-Diagnostics
CODX
|
222 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Danaher Corporation
DHR
|
10 B | $ 189.05 | -1.58 % | $ 135 B | USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
DexCom
DXCM
|
1.86 B | $ 63.32 | 0.17 % | $ 24.7 B | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 24.75 | 0.08 % | $ 687 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 15.98 | -2.68 % | $ 483 M | USA |
 |
Guardant Health
GH
|
349 M | $ 90.17 | 0.56 % | $ 11.3 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 107.87 | -1.6 % | $ 8.9 B |  Irlanda |
 |
Illumina
ILMN
|
1.51 B | $ 126.04 | -1.33 % | $ 20 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.13 | -1.84 % | $ 4.89 M | USA |
 |
BioNano Genomics
BNGO
|
15.3 M | $ 1.15 | -0.43 % | $ 6.26 M | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.98 | 0.51 % | $ 8.76 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 271.93 | -0.96 % | $ 22.6 B | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 76.19 | 0.4 % | $ 5.14 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.64 | -0.54 % | $ 430 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 7.9 | -1.5 % | $ 1.01 B | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 9.93 | 3.82 % | $ 2.15 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 198.9 | -0.08 % | $ 22.1 B | USA |
 |
Natera
NTRA
|
158 M | $ 206.47 | 0.78 % | $ 20.3 B | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 4.71 | -0.74 % | $ 3.71 M | USA |
 |
Pacific Biosciences of California
PACB
|
114 M | $ 1.42 | - | $ 426 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 26.78 | -1.58 % | $ 20 B | Niderland |
 |
Precipio
PRPO
|
13.3 M | $ 26.03 | 0.19 % | $ 41.8 M | USA |
 |
Personalis
PSNL
|
57.8 M | $ 6.03 | -8.36 % | $ 357 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |